Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease (ASCVD). Recent acquisitions and ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its ...

2025年第67届ASH年会将于12月7日-10日在美国奥兰多召开。ASH作为全世界血液学工作者的盛会，每年都会公布和发表世界各国的最新血液学进展。届时将汇集各国知名血液病学专家，分享全球最前沿的研究进展和突破性临床数据。

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

New research uncovers the exact immune-to-brain pathway that drives the loss of social motivation during sickness.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

By Dengyuemed International Business Department  November 28 — The National Medical Products Administration (NMPA) has approved the marketing of picankibart injection, an innovative IL-23p19–targeting ...

A new study published in the Journal of Cannabis Research and U.S. Library of Medicine reports that cannabidiol may reduce ...

Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused ...